ESR1 and breast neoplasm: As FOXA1 is one of the early events in the ER pathway activation cascade, it might be possible that the oncogenic nature of ER pathway activation is already established in early neoplasia and continues to IDC as FOXA1 and GATA3 are frequently mutated in ER+/luminal breast tumors [42].